IRI — Integrated Research Income Statement
0.000.00%
Last trade - 00:00- AU$65.62m
- AU$26.77m
- AU$68.26m
- 71
- 98
- 17
- 69
Annual income statement for Integrated Research, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 78.5 | 62.9 | 69.8 | 83.3 | 68.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 70 | 67.1 | 101 | 58.8 | 52.8 |
| Operating Profit | 8.47 | -4.27 | -31.5 | 24.5 | 15.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 9.31 | -2.44 | -29.3 | 26.7 | 18.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 7.93 | 1.54 | -29.2 | 27.1 | 13.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 7.93 | 1.54 | -29.2 | 27.1 | 13.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 7.93 | 1.54 | -29.2 | 27.1 | 13.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.043 | 0.004 | -0.05 | 0.152 | 0.071 |
| Dividends per Share |